| Today's News and Trends | The study’s authors tracked data from nearly 16,000 patients who underwent PCI from 2010 to 2023. This is believed this to be the largest comparison of intravascular imaging-guided PCI and angiography-guided PCI to date. The study’s authors tracked data from nearly 16,000 patients who underwent PCI from 2010 to 2023. This is believed this to be the largest comparison of intravascular imaging-guided PCI and angiography-guided PCI to date. | |
| The veteran cardiologist had been worried that cerebral protection devices were only being used to treat TAVR patients with specific insurance plans. The lawsuit has now been resolved to the “mutual satisfaction” of both parties. The veteran cardiologist had been worried that cerebral protection devices were only being used to treat TAVR patients with specific insurance plans. The lawsuit has now been resolved to the “mutual satisfaction” of both parties. | |
| Ismail El-Hamamsy, MD, PhD, said he hopes to spend his time as HVS president focused on fostering collaborations and encouraging innovation. Ismail El-Hamamsy, MD, PhD, said he hopes to spend his time as HVS president focused on fostering collaborations and encouraging innovation. | |
| The company officially launched its Cleerly ISCHEMIA software for delivering noninvasive evaluations of CCTA exams in early 2024. This update provides a closer look at the software from a billing perspective. The company officially launched its Cleerly ISCHEMIA software for delivering noninvasive evaluations of CCTA exams in early 2024. This update provides a closer look at the software from a billing perspective. | |
| | Alain Cribier, MD, a veteran interventional cardiologist out of France, died at the age of 79. The procedure he helped put on the map is arguably cardiology's most significant breakthrough in the last several decades. Alain Cribier, MD, a veteran interventional cardiologist out of France, died at the age of 79. The procedure he helped put on the map is arguably cardiology's most significant breakthrough in the last several decades. | |
| Any devices that claim to make blood glucose measurements without piercing the user's skin are associated with a heightened risk of error, the agency said. Any devices that claim to make blood glucose measurements without piercing the user's skin are associated with a heightened risk of error, the agency said. | |
| LumiGuide uses fiber optic realShape (FORS) technology, where light is reflected along an optical fiber inside a guidewire to generate 3D, high-resolution, color images of devices inside a patient’s body LumiGuide uses fiber optic realShape (FORS) technology, where light is reflected along an optical fiber inside a guidewire to generate 3D, high-resolution, color images of devices inside a patient’s body | |
| Despite an expanded indication from the FDA and lower prices, patient access to these cholesterol-lowering medications remains a significant issue. Despite an expanded indication from the FDA and lower prices, patient access to these cholesterol-lowering medications remains a significant issue. | |
| | Marielle Scherrer-Crosbie, MD, explains what is needed to create a cardio-oncology program, and the role played by cardiac imagers. Marielle Scherrer-Crosbie, MD, explains what is needed to create a cardio-oncology program, and the role played by cardiac imagers. | |
| A Washington woman was pulled over and arrested because a state trooper thought she was driving under the influence. It turned out that she was not drunk, but suffering from a frontal-lobe subdural hematoma. She has now filed a lawsuit against the county. A Washington woman was pulled over and arrested because a state trooper thought she was driving under the influence. It turned out that she was not drunk, but suffering from a frontal-lobe subdural hematoma. She has now filed a lawsuit against the county. | |
| | DeepLook Medical has developed what it claims is the first technology platform for assessing suspicious masses in such clinical scenarios. DeepLook Medical has developed what it claims is the first technology platform for assessing suspicious masses in such clinical scenarios. | |
| Here’s what people have been saying about Nvidia’s gradual-then-sudden rise to riches—and what it says about expectations around AI in 2024. Here’s what people have been saying about Nvidia’s gradual-then-sudden rise to riches—and what it says about expectations around AI in 2024. | |
| |
|
| | |
|